RxDoctor Payments DataLook up a doctor →

Gerald Asin, MD

Internal Medicine · Paradise Valley, AZNPI 1770576365

Payments from drug & device makers

$252,778in general payments, 2019–2025

Across 1,403 payments — averaging $180.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$115K
  • Merck$73K
  • Abbott$22K
  • Boehringer Ingelheim$8K
  • Eisai Inc.$6K
  • AbbVie$5K
  • plus $23K from 54 others
$99,283in research payments, 2019–2025

Across 1 payment — averaging $99,283 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$99K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly3$115,354
Merck14$73,111
Abbott32$21,820
Boehringer Ingelheim71$7,789
Eisai Inc.16$5,509
AbbVie(2 entities)284$5,419
Novo Nordisk86$3,004
Shionogi Inc2$2,338
Lilly USA, LLC99$2,090
Amgen101$1,608
Biohaven Pharmaceuticals, Inc.20$1,417
Pfizer83$1,076
AstraZeneca45$1,006
Johnson & Johnson40$881
GSK49$879
Bayer30$814
Sanofi-aventis U.S. LLC28$793
Takeda Pharmaceuticals U.S.A., Inc.48$779
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC39$683
Novartis27$525
Astellas Pharma US Inc10$486
Gilead11$352
Antares Pharma, Inc.23$263
Sumitomo Pharma America, Inc.9$208
Nestle Healthcare Nutrition Inc.13$197
Mannkind Corporation10$187
Biohaven Pharmaceutical Holding Company Ltd.16$179
Amarin Pharma, Inc.11$178
Dexcom, Inc.6$173
Avanir Pharmaceuticals, Inc.5$171
Corcept Therapeutics7$149
Clarus Therapeutics Inc.3$149
Esperion Therapeutics, Inc.9$148
Octapharma USA, Inc.2$144
Lundbeck LLC8$140
Teva Pharmaceuticals USA, Inc.7$131
Otsuka America Pharmaceutical, Inc.6$127
Radius Health, Inc.6$127
Aimmune Therapeutics, Inc.6$126
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)7$125
Axsome Therapeutics, Inc.5$124
Tolmar, Inc.6$121
Almatica Pharma LLC1$114
Lucid Diagnostics Inc.5$109
Alfasigma USA, Inc.6$106
Bausch Health US, LLC6$106
Currax Pharmaceuticals LLC7$99
Scilex Pharmaceuticals Inc.4$95
Exact Sciences5$95
Ironwood Pharmaceuticals, Inc6$94
Medtronic(2 entities)5$93
Therapeuticsmd, Inc.5$83
Intra-sana Laboratories5$79
Impel Pharmaceuticals Inc.4$79
Boston Scientific3$70
Idorsia Pharmaceuticals US Inc4$66
Shire North American Group Inc3$57
BD3$50
Xeris Pharmaceuticals, Inc.2$43
Axonics, Inc.2$42

How this compares

$252,778 in reported general payments places this provider in the 95th percentile of 2,212 internal medicine providers in Arizona.

See all internal medicine providers in Arizona →

Medicare billing

Part B allowed, 2024
$429,075
Medicare patients
1,179
Services billed
4,833

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other internal medicine in Paradise Valley

See the full list for Arizona →

Where these figures come from

Is this you, or does something look wrong? →